Clinical Study | Office of Clinical Research

An Ongoing, 5-Year Post Market Study To Track Clinical Application, Of Decisiondx-Melanoma Gene Expression Profile (Gep) Assay Results And The Impact

Posted Date: May 15, 2019

Investigator: Jeffrey Sussman
Type of Study: Drug

The DecisionDx-CM gene expression assay (test) evaluates the gene expression pattern of an individual patient?s tumor tissue and classifies it as low risk (Class 1) or high risk (Class 2). With this information, a doctor and patient together can make important decisions about treatment planning.

Criteria:

To Be Eligible For This Study, Patients Must Have Cutaneous Melanoma (A Type Of Skin Cancer).

Keywords:

Integrate, Cancer, Skin Cancer, Melanoma

For More Information:

Uc Cancer Center
513-584-7698
kastla@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List